TB Archives – Page 21 of 49 – Treatment Action Group

TAG's Erica Lessem and Annette Gaudino being arrested for civil disobedience as part of the "Delancey 14."

Treatment Action Group Joins Collective Call Denouncing the Trump Administration’s Dangerous Finalized Anti-Immigrant Rule

August 19, 2019
Chad Cipiti

Treatment Action Group (TAG) strongly opposes the administration’s finalized rule “Inadmissibility on Public Charge Grounds.” This rule, which goes into effect on October 15, 2019, dangerously expands the definition of immigrants who are ineligible for admission into the U.S. or adjustment of status to include those who seek basic public services for health, nutrition, and housing.

Statement from Treatment Action Group on U.S. FDA Approval of Pretomanid

August 14, 2019
Chad Cipiti

Treatment Action Group welcomes simpler, shorter treatment options for people with some forms of drug-resistant tuberculosis, while urging additional research and equitable access.

The Tuberculosis Vaccines Pipeline

July 23, 2019
Chad Cipiti

June 2013 Where are we going, where have we been? By Mike Frick Since the 2012 Pipeline Report, results from phase II trials and advances in preclinical development have brought the pipeline for new TB vaccines into sharper focus, even…

The Tuberculosis Treatment Pipeline

July 23, 2019
Chad Cipiti

June 2013 Better than Ever Is Not Good Enough By Erica Lessem NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2013. Introduction In December 2012, tuberculosis (TB) treatment reached a historic…

The Tuberculosis Diagnostics Pipeline

July 23, 2019
Chad Cipiti

June 2013 By Colleen Daniels Currently, smear microscopy and mycobacterial culture are the most widely used diagnostic tests, but microscopy, though relatively fast, is too inaccurate—missing over half of cases1—while culture is accurate but slow, taking from two to eight…

The Tuberculosis Vaccines Pipeline

July 22, 2019
Chad Cipiti

July 2014 Back to basic science By Mike Frick The last year in tuberculosis (TB) vaccine research has demonstrated how setbacks can sometimes produce the potential for unexpected progress. Dominant hypotheses have yielded to new investigative directions, and unresolved questions…

Playing Catch-Up: The Pediatric Tuberculosis Treatment Pipeline

July 22, 2019
Chad Cipiti

July 2014 By Lindsay McKenna Introduction While the pediatric HIV drug pipeline has seen increased activity in recent years, the same cannot be said for pediatric TB. Adult-pediatric approval gaps remain an issue in HIV drug development, especially for children…

Tuberculosis Drug Development Hobbles Forward

July 22, 2019
Chad Cipiti

July 2014 By Erica Lessem Introduction After forty years without new approved drug classes, tuberculosis (TB) treatment has recently advanced with the approval of two new compounds to treat multidrug-resistant TB (MDR-TB): delamanid and bedaquiline.1,2,3 Yet with limited access to…

The Tuberculosis Diagnostics Pipeline

July 22, 2019
Chad Cipiti

July 2014 By Colleen Daniels Accurate diagnosis of tuberculosis (TB) is the gateway to treatment and—it is hoped—cure for people with latent TB infection (LTBI) or active TB disease. According to the Stop TB Partnership and the World Health Organization…

The Tuberculosis Vaccines Pipeline: A New Path to the Same Destination?

July 22, 2019
Chad Cipiti

July 2015 By Mike Frick Call it a paradigm shift, a pivot, or a turn – tuberculosis (TB) vaccine research and development (R&D) is entering a period of basic science. After years of focusing on phase II clinical trials, some…